National Institute On Drug Abuse (Nida) was Avalo Therapeutics’s largest revenue line in fiscal 2016, bringing in $3.06M of $3.46M (89%).
| Research and Development Arrangement, Contract to Perform for Others, Type | FY 2016 |
|---|---|
| National Institute On Drug Abuse (Nida) | $3.06M |
| National Institute On Alcohol Abuse & Alcoholism (Niaaa) | $396.00K |
| Total | $3.46M |
Avalo Therapeutics brought in $3.46M from its two revenue lines in fiscal 2016, the year ended December 31, 2016. National Institute On Drug Abuse (Nida) was the largest at $3.06M (88.5%), ahead of National Institute On Alcohol Abuse & Alcoholism (Niaaa) at $396.00K (11.5%).
Avalo Therapeutics (AVTX) reports its revenue by research and development arrangement, contract to perform for others, type. In fiscal 2016, National Institute On Drug Abuse (Nida) was its largest revenue line, bringing in $3.06M (88.5% of the total), followed by National Institute On Alcohol Abuse & Alcoholism (Niaaa) at $396.00K (11.5%).
National Institute On Drug Abuse (Nida) was Avalo Therapeutics' largest revenue line in fiscal 2016, bringing in $3.06M, or 88.5% of the $3.46M total across its two revenue lines.
Every figure comes from Avalo Therapeutics' annual financial filings, as reported. Each line keeps the name Avalo Therapeutics gives it, and years follow its fiscal calendar.
Avalo Therapeutics' revenue by research and development arrangement, contract to perform for others, type goes back to fiscal 2016, with figures through fiscal 2016. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.